Loading…
← CockpitCompetitor Analysis › EMCURE.NS Emcure PharmaceuticalsOpen in the cockpit ↗

Emcure PharmaceuticalsEMCURE.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Generic pharmaceutical company focused on women's health, cardiology and vaccines, sold domestically and exported.

≈ A women's-health-focused Indian generics makerMomentum leader 94
Mkt cap
$4.74B
US dollars, full cap
Free float
19%
of shares outstanding
$/day
$7.07M
20-day average traded
Fwd P/E
33.6×
forward earnings
ROIC−WACC
+7.8 pp
WACC 9.4%
Hurdle
+3 pp
Req g minus delivered
Next earnings
85 days
11 Feb 2027
Close · INR₹2,335
1D-0.2%
1W+4.6%
1M+32.2%
3M+24.6%
6M+36.5%
YTD+71.1%
1Y+74.6%
ATR %3.6%
Beta0.46
52w lowhigh3.9% off high

What Emcure Pharmaceuticals does

Generic pharmaceutical company focused on women's health, cardiology and vaccines, sold domestically and exported.

Sells branded generics, off-patent drugs marketed under its own names, mostly in India, where doctors' prescriptions and a large field sales force drive demand; it also sells abroad. Listed in 2024, it has had Bain Capital as an investor, and runs a vaccine subsidiary, Gennova.

In one line: A women's-health-focused Indian generics maker.

Products and services

  • Women's health formulations
  • Cardiology/HIV drugs
  • Vaccines (via Gennova)

Customers

  • Doctors/hospitals in India
  • Export markets (emerging economies)

Where it sits in the supply chain

  • Formulation R&D
  • Generic drug manufacturing
  • Domestic & export distribution

What could go right

  • Domestic branded generics growth
  • Export market expansion

What could go wrong

  • Government price controls
  • Generic price erosion

Moat: narrow (brand, distribution). Established prescriber relationships in women's health, a therapy area with fewer large competitors.

Headquarters: Pune, India · Founded: 1981 · Employees: 6,914

Named competitors

Emcure Pharmaceuticals at a glance

Size Emcure Pharmaceuticals (EMCURE.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $4.74B, the 219th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹2,335 on 18 Nov 2026.

Performance Over six months the shares gained 36.5%, against +5.6% for the median peer and +3.8% for the India market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 21.1% over the last twelve months (peer median +9.5%); the operating margin is 15.6% (peer median 17.1%).

Valuation It trades at 33.6× forward earnings against a peer median of 21.5× (5th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 7.8 points above its cost of capital (9.4% WACC).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026EMCURE.NS 135Peer median 107
Six months, rebased to 100: Emcure Pharmaceuticals against the median of its 20 peers (local-currency closes).

Emcure Pharmaceuticals financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹102B₹91.3B₹78.2B₹65.9B₹59.4B
Revenue growth—+17%+19%+11%—
Gross profit₹40.0B₹29.2B₹23.5B₹21.1B₹19.3B
EBITDA₹20.3B₹17.2B₹14.0B₹11.8B₹11.5B
Net income₹10.9B₹9.24B₹6.81B₹4.98B₹5.32B
Free cash flown/a₹4.90B₹5.24B₹6.31B₹1.83B
Capital expendituren/a₹5.48B₹4.07B₹3.07B₹4.03B
Total debt₹17.6B₹15.2B₹10.2B₹23.2B₹23.2B

Quarterly statements and history in the cockpit →

Emcure Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%0%+20%GLAXOTVTXERAS600079600085IONS0874IPCALABPTCT326030LQDAAJANTPHARM600566CAMX002294MANE6885784536EMCURE.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Emcure Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%+800%20×40×GLAXOTVTX6000796000850874IPCALAB326030LQDACAMX0022946885784506000100EMCURE.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Emcure Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+200%+400%0%200%400%GLAXOTVTX600079600085326030LQDA688578EMCURE.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Emcure Pharmaceuticals is the large dot.

Emcure Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (EMCURE.NS vs SUNPHARMA.NS vs CIPLA.NS vs MANKIND.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Emcure Pharmaceuticals EMCURE.NS$4.74B+37%+21%16%33.6×15.9%
Sun Pharmaceutical Industries SUNPHARMA.NS$48.0B-1%+12%23%36.0×28.7%
Cipla CIPLA.NS$12.2B+1%-1%13%29.1×28.4%
Mankind Pharma MANKIND.NS$11.6B+5%+13%21%44.4×28.6%

How Emcure Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Emcure Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureEMCURE.NSPeer medianRank in peer set
1-month return+32.2%-1.3%2nd highest of 21
6-month return+36.5%+5.6%highest of 21
Distance from 52-week high-3.9%-33.5%3rd highest of 21
Revenue growth (TTM)+21.1%+9.5%6th highest of 19
Operating margin15.6%17.1%9th lowest of 19
Forward P/E33.6×21.5×5th most expensive of 18
Growth the price implies (Req g, 7 yrs)15.9%3.4%5th most demanding of 17
Growth delivered (Del g)+12.7%+10.9%8th highest of 17
Hurdle (Req g minus delivered)+3.2 pp-6.3 pp5th most demanding of 17
ROIC minus cost of capital+7.8 pp+3.4 pp6th highest of 17
EV / EBITDA22.6×18.7×5th most expensive of 11
Net debt / EBITDA0.8×-0.8×3rd most indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Emcure Pharmaceuticals EMCURE.NSIndia$4.74B+37%+21%16%33.6×15.9%+12.7%
GlaxoSmithKline Pharmaceuticals GLAXO.NSIndia$4.79B+10%+12%33%37.3×26.4%+5.5%
Travere Therapeutics TVTXUnited States$4.82B+16%+49%-3%17.1×17.3%+19.9%
Erasca ERASUnited States$4.83B+24%n/an/an/an/an/a
Humanwell Healthcare (Group) 600079.SSChina$4.87B+11%+2%15%13.8×-8.8%+3.0%
Beijing TongRenTang 600085.SSChina$4.91B-12%-17%8%28.7×1.7%+6.2%
Ionis Pharmaceuticals IONSUnited States$4.56B-64%-1%-59%n/an/an/a
Guangzhou Baiyunshan Pharmaceutical 0874.HKHong Kong$4.48B-23%+6%3%7.0×1.3%+4.0%
IPCA Laboratories IPCALAB.NSIndia$5.03B+12%+12%18%31.1×16.5%+12.2%
PTC Therapeutics PTCTUnited States$5.03B-15%-35%22%31.2×6.6%+35.4%
SKBP 326030.KSSouth Korea$5.03B-16%+37%38%21.5×-4.4%+93.6%
Liquidia LQDAUnited States$5.08B-9%+798%47%13.8×5.0%+192.5%
Ajanta Pharma AJANTPHARM.NSIndia$4.38B+1%+25%25%31.7×23.8%+13.8%
HUBEI JUMPCAN PHARMACEUTICAL 600566.SSChina$4.36B+12%-4%32%16.2×-9.9%+0.3%
Camurus CAMX.STSweden$4.36B+36%+3%38%45.1×7.9%+46.5%
Shenzhen Salubris Pharmaceuticals 002294.SZChina$4.31B-24%+14%11%35.4×12.4%+9.7%
Veradermics MANEUnited States$5.27B+19%n/an/an/an/an/a
Shanghai Allist Pharmaceuticals 688578.SSChina$5.32B-14%+39%47%12.4×0.1%+519.6%
Sumitomo Pharma 4506.TJapan$5.33B+11%+11%10%8.6×1.7%-2.6%
Santen Pharmaceutical 4536.TJapan$4.14B+10%+2%16%16.7×-5.0%+3.2%
Yuhan 000100.KSSouth Korea$4.11B-10%+8%6%40.4×n/an/a

Questions

Who are Emcure Pharmaceuticals's main competitors?
Named competitors: Sun Pharma (SUNPHARMA.NS), Cipla (CIPLA.NS), Mankind Pharma (MANKIND.NS). The cockpit's measured peer set (industry) also includes GlaxoSmithKline Pharmaceuticals (GLAXO.NS), Travere Therapeutics (TVTX), Erasca (ERAS), Humanwell Healthcare (Group) (600079.SS), Beijing TongRenTang (600085.SS), Ionis Pharmaceuticals (IONS).
Is Emcure Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 33.6× against a peer median of 21.5×, 5th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Emcure Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +36.5% against +5.6% for the median peer; over one year +74.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.